As measles cases continue to rise across the United States and globally, NanoViricides, Inc. (NYSE American: NNVC) is advancing its NV-387 measles treatment program toward clinical trials. The company announced it is developing a Phase II clinical trial protocol and intends to submit it to the U.S. Food and Drug Administration (FDA) through an Investigational New Drug (IND) application. This move comes at a critical time when public health officials are grappling with resurgent measles outbreaks, underscoring the urgent need for effective antiviral treatments.
NV-387 has demonstrated strong in vivo activity against lethal measles infection in a humanized animal model, according to the company. The drug candidate has also received both Orphan Drug Designation (ODD) and Rare Pediatric Disease Drug (RPDD) Designation from the FDA for the treatment of measles. The RPDD designation is particularly significant because it could make NanoViricides eligible for a Priority Review Voucher upon approval of a qualifying marketing application, provided applicable requirements are met. This voucher can be sold or transferred, potentially providing substantial financial benefits.
The advancement of NV-387 is part of NanoViricides' broader strategy to develop broad-spectrum antivirals based on its host-mimetic nanomedicine technology. The company's lead drug candidate, NV-387, is being developed as a treatment for multiple viral infections, including respiratory syncytial virus (RSV), COVID-19, long COVID, influenza, and other respiratory viral infections, as well as MPOX/smallpox and measles. The technology behind NV-387 involves nanoviricide particles that mimic host cell surfaces, attracting and neutralizing viruses.
The measles treatment program is particularly timely given the recent rise in measles cases. In the U.S., measles was declared eliminated in 2000, but vaccination gaps have led to outbreaks in recent years. Globally, measles remains a significant cause of death among young children, despite the availability of a safe and effective vaccine. The World Health Organization has reported a resurgence of measles in multiple regions, driven by disruptions in vaccination programs due to the COVID-19 pandemic and vaccine hesitancy.
NanoViricides' progress with NV-387 is noteworthy because there are currently no specific antiviral treatments for measles. Standard care is supportive, and severe cases can lead to complications such as pneumonia, encephalitis, and death. An effective antiviral could be crucial for immunocompromised individuals, pregnant women, and unvaccinated populations who are at higher risk.
The company's pipeline also includes NV-HHV-1 for shingles, and it is developing drugs against a range of other viral diseases, including herpes, viral eye infections, influenza, HIV, hepatitis C, rabies, dengue fever, and Ebola. NanoViricides holds a worldwide exclusive perpetual license to its platform technology from TheraCour Pharma, Inc., for multiple viruses. The company's business model relies on licensing technology for specific applications.
As NanoViricides moves NV-387 toward Phase II trials, it will need to navigate the lengthy and capital-intensive drug development process. The company acknowledges that there can be no assurance that its pharmaceutical candidates will demonstrate sufficient effectiveness and safety for human clinical development or achieve regulatory approval. However, the progress of NV-387 and the regulatory designations it has received highlight its potential as a much-needed therapeutic option for measles, a disease that continues to pose a global health threat.
For more information about NanoViricides and its programs, visit the company's newsroom at https://ibn.fm/NNVC.
